Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Summary

This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line chemotherapy other than a cetuximab containing regimen will be treated with standard of care weekly cetuximab and twice daily low dose oral cyclophosphamide for 12 weeks.

Timeline

Start

2012-06

Primary completion

2015-09

Completion

2015-09

Drugs

Indications